The Supreme Court is set to hear oral arguments today in a case that could determine whether companies have the right to patent human genes. The specific dispute involves Myriad Genetics' patents on two genes linked to breast and ovarian cancer. Critics of gene patents said that patents should not be allowed on parts of the human body and that patents impede medical progress. Myriad Genetics and its supporters, including BIO, meanwhile, said that a ruling against gene patents could force companies to stop investing in genetics research, to the detriment of patients and also the economy.
Published in Brief: